Tissuemed

Tissuemed is a British medical technology company that develops tissue-based therapeutic devices and bioadhesive films used in operations.

History

2021: Becton Dickinson bought Tissuemed

On December 9, 2021, Becton Dickinson announced the acquisition of the developer of self-adhesive surgical sealing films Tissuemed. The purchase is aimed at expanding global offerings for surgeons outside the United States at the expense of the company's main product, Tissuepatch. The amount of the transaction was not disclosed.

Tissuemed has developed the Thissuepatch product as a patented sealing technology that glues tissues together to help control internal bleeding or prevent leaks from surgical incisions. As stated in the press release, the thinner, flexible and transparent composition of Tissuepatch is ready for use from packaging, which makes the product the best for a number of applications in the field of surgery. The product is designed for use along with suturing and surgical clamps to minimize postoperative leaks of all kinds. For example, Tissuepatch could help close the protective tissue surrounding the brain and spine to fix cerebrospinal fluid or prevent air from exiting the lung tissue after thoracic surgeries.

Becton Dickinson acquired Tissuemed

This advanced sealant serves as a strategic addition to the Becton Dickinson products used in the operating room and gives us the opportunity to provide surgeons with a more robust, highly integrated portfolio of surgical solutions. Tissuepatch's integration into our business is consistent with our commitment to continuously innovate our core portfolio to help support minimally invasive surgeries, said Becton Dickinson President of Surgery Kevin Kelly.

According to representatives of Becton Dickinson, surgeons already trust Tissuepatch with its design that provides strong adhesion and minimal swelling, which gives the company the opportunity to use its reach and clinical experience to further progress in sealing technologies. Becton Dickinson noted that the deal will be insignificant for the results of fiscal 2022.^[1]

Notes